Direct Load Tube Collection Kit

    No uncapping.
    No specimen transfer.

    Placeholder image

      Overview

      Package Inserts

      Transform Specimen Processing for COVID Testing

      No uncapping and no specimen transfer. Expedite your SARS-CoV-2* workflow with a collection device that loads directly on the Panther® system. The Direct Load Tube Collection Kit is authorized for use with the Aptima® SARS-CoV-2 and Aptima SARS-CoV-2/Flu assays. 

      Deliver Results Sooner

      Load directly into the Panther System.

      • Directly load alongside specimen types for other assays with true random and continuous access.
      • Non-hazardous lysis buffer reduces risk by inactivating common respiratory viruses, minimizing biosafety needs.
      • Penetrable cap eliminates uncapping and recapping of tube.

      Traditional 8-Step Respiratory Specimen Workflow

      1

      Uncap Collection Tube

       

      2

      Uncap Transfer Tube

       

      3

      Transfer Primary Specimen

       

      4

      Recap Transfer Tube

       

      5

      Recap Collection Tube

       

      6

      Mix Transfer Tube

       

      7

      Uncap Transfer Tube

       

      8

      Load Onto System

       

      Reduce Labor/Costs/Risk with Fewer Steps

      • Eliminate manual uncapping and recapping.
      • One collection kit for nasal and OP swabs.
      • Remove manual specimen transfer steps.
      • Inactivates common respiratory viruses.
      • Reduce human error and repetitive motion injuries.
      • Guanidine free, non-toxic media.
      • Reduce costs for additional consumables.       
      • Penetrable cap serves as additional cross-contamination barrier.
      * The Aptima SARS-CoV-2 and Aptima SARS-CoV-2/Flu assays have not been FDA cleared or approved; These tests have been authorized by FDA under an EUA for use by authorized laboratories; The Aptima SARS-CoV-2 assay has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens; The Aptima SARS-CoV-2/Flu assay  has been authorized only for the simultaneous qualitative detection and differentiation of nucleic acid from SARS-CoV-2, Flu A and Flu B and not for any other viruses or pathogens. The Aptima SARS-CoV-2 and Aptima SARS-CoV-2/Flu assays are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.